Developer docs
API playgroundTry for free, no card

Search company profiles

Splice Bio

Full company profile

uuid000089n

Namestring
Splice Bio
Legal namestring
SPLICEBIO, S.L.
Websiteurl
splice.bio
Company typeenum
Private
Founded yearint
2014
Descriptiontext

SpliceBio is a clinical-stage genetic medicines company headquartered at the Parc Científic de Barcelona, Spain, founded in 2014 (originally as ProteoDesign) by Miquel Vila-Perelló and Silvia Frutos. The company develops gene therapies for rare genetic diseases using its proprietary Protein Splicing platform, a technology based on engineered split inteins originating from over 20 years of research at Princeton University's Muir Lab. SpliceBio's lead clinical program, SB-007, is a dual AAV gene therapy candidate in Phase 1/2 development (ASTRA study) for Stargardt disease, with the potential to treat all patients regardless of ABCA4 mutation type. The platform addresses a fundamental limitation in gene therapy: standard AAV vectors cannot package genes exceeding 4.7 kb, and SpliceBio's split intein technology reconstitutes full-length therapeutic proteins from dual AAV vectors in vivo.

SpliceBio's technology foundation combines engineered split inteins with additional proprietary elements enabling efficient delivery of large genes via dual AAV vectors, a platform that has been validated across multiple organs beyond the retina. The pipeline targets ophthalmology and neurology indications, and SB-007 has received FDA Orphan Drug Designation, FDA Fast Track Designation, European Commission Orphan Drug Designation, FDA IND clearance (the first-ever for a Protein Splicing gene therapy), and UK MHRA clearance. The company is supported by the POLARIS natural history study to streamline clinical trial enrollment.

SpliceBio is a privately held, pre-revenue biotech with no commercialized products. Its near-term revenue model is one-time licensing — exemplified by the October 2023 exclusive worldwide collaboration and licensing agreement with Spark Therapeutics for an undisclosed inherited retinal disease, eligible for up to $216 million in upfront, opt-in, and milestone payments plus royalties. Future revenue will derive from commercialization of SB-007 and pipeline gene therapy products, with pricing expected to be consistent with high-cost one-time gene therapies (industry reference points such as CSL's $3.5M hemophilia B therapy). The company pursues clinical trial site engagement, regulatory interactions, and biopharma partnerships, and is backed by over $200 million in total funding from top-tier investors including EQT Life Sciences, Sanofi Ventures, Roche Venture Fund, NEA, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.

Short descriptiontext

SpliceBio is a clinical-stage genetic medicines company developing gene therapies for rare genetic diseases using its proprietary Protein Splicing platform based on engineered split inteins from Princeton University. Its lead program, SB-007, is in Phase 1/2 trials for Stargardt disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy platform, protein splicing technology, dual AAV vectors, ophthalmology therapeutics, rare disease treatments
Industry2 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Genetic Medicines / Gene Therapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue will be generated through commercialization of gene therapy products, primarily SB-007 for Stargardt disease and future pipeline programs in ophthalmology, neurology, and other therapeutic areas. Additional potential revenue from licensing agreements and milestone payments from partnerships.

splice.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SpliceBio is a clinical-stage genetic medicines company developing gene therapies using its proprietary Protein Splicing platform based on engineered split inteins developed at Princeton University's Muir Lab. The platform enables delivery of large genes exceeding the 4.7 kb packaging capacity of standard AAV vectors by splitting genes across dual AAV vectors and reconstituting full-length therapeutic proteins in vivo via protein trans-splicing. The lead clinical candidate SB-007 is a dual AAV gene therapy for Stargardt disease currently in Phase 1/2 ASTRA clinical development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First patient dosed in Phase 1/2 ASTRA clinical trial in March 2025 - first dual AAV gene therapy for Stargardt disease to enter clinical development
+2 more records
Product overview1 text field

SpliceBio is a clinical-stage genetic medicines company offering a proprietary Protein Splicing platform technology and a pipeline of gene therapy programs. The core platform enables delivery of large genes using dual AAV vectors with engineered split inteins that reconstitute full-length therapeutic proteins in vivo. The lead product is SB-007, a dual AAV gene therapy for Stargardt disease currently in Phase 1/2 clinical development (ASTRA study), supported by the POLARIS natural history study. Additional pipeline programs span ophthalmology and neurology therapeutic areas.

Product and service2 records
1SB-007
CategoryGene Therapy Product Candidate
Description

Lead dual AAV gene therapy candidate for Stargardt disease that uses protein splicing technology to restore expression of full-length ABCA4 protein in retinal photoreceptor cells, with potential to treat all patients regardless of ABCA4 mutation type. Currently in Phase 1/2 ASTRA clinical trial; administered via subretinal injection.

2Protein Splicing Platform
CategoryGene Therapy Technology Platform
Description

Proprietary gene therapy technology platform based on engineered split inteins that enables delivery of large genes exceeding the 4.7 kb packaging capacity of standard AAV vectors. Splits large genes into multiple transgenes delivered via dual AAV vectors, which are reconstituted into full-length therapeutic proteins through protein trans-splicing in vivo. Licensed to biopharmaceutical partners for development of gene therapies in ophthalmology, neurology, and other therapeutic areas.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-17
Description

Exclusive collaboration and licensing agreement to utilize SpliceBio's Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Spark has exclusive worldwide rights to develop, manufacture, and commercialize. SpliceBio eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical and commercial-stage AAV gene therapy company with a broad pipeline including ophthalmology assets (e.g., RGX-314 for wet AMD/DR). Direct platform peer in AAV-based gene therapy for rare diseases including inherited retinal conditions.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company focused on ocular diseases (wet AMD, diabetic retinopathy). Directly comparable as an ophthalmology-focused AAV gene therapy peer at a similar clinical stage with intravitreal delivery approaches.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company developing ultevursen (formerly QR-421a) for Stargardt disease and other ophthalmology programs. Most direct competitor for SpliceBio's SB-007 lead indication, using antisense oligonucleotides rather than AAV gene therapy.

TypeDirect peer
Description

Clinical and commercial-stage AAV gene therapy company (Hemgenix approved for hemophilia B). Comparable as a rare-disease AAV gene therapy platform with similar regulatory, manufacturing, and capital-intensity dynamics.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company focused on CNS and rare neurological diseases with proprietary capsid engineering. Similar stage and business model to SpliceBio, using engineered AAV vectors for hard-to-treat monogenic indications.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company developing treatments for rare CNS disorders, partnered with Penn's Gene Therapy Program. Comparable clinical-stage AAV peer in monogenic rare diseases.

TypeDirect peer
Description

Clinical-stage gene therapy company with a broad AAV-based pipeline across CNS and rare diseases. Comparable clinical-stage AAV gene therapy peer with similar platform strategy and indication breadth.

TypeEmerging player
Description

Clinical-stage gene therapy company developing optogenetic therapies for retinal diseases including Stargardt disease (MCO-010). Directly competing in the same lead indication with an alternative gene-therapy-based mechanism.

TypeEmerging player
Description

Clinical-stage non-viral gene therapy company using cell-targeted lipid nanoparticles (ctLNP) for large-gene delivery, including in ophthalmology and hemophilia. Emerging competitor pursuing the same large-gene delivery opportunity as SpliceBio but via a non-AAV modality.

TypeBroad incumbent
Description

Large rare-disease-focused biopharmaceutical company with a commercial gene therapy product (Roctavian for hemophilia A) and pipeline spanning ophthalmology, CNS, and metabolic rare diseases. A broader incumbent in the rare-disease gene therapy commercial landscape that SpliceBio's lead program could eventually compete in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Splice Bio

Genetic Medicines / Gene Therapysplice.bio

SpliceBio is a clinical-stage genetic medicines company developing gene therapies for rare genetic diseases using its proprietary Protein Splicing platform based on engineered split inteins from Princeton University. Its lead program, SB-007, is in Phase 1/2 trials for Stargardt disease.

What Splice Bio does

SpliceBio is a clinical-stage genetic medicines company headquartered at the Parc Científic de Barcelona, Spain, founded in 2014 (originally as ProteoDesign) by Miquel Vila-Perelló and Silvia Frutos. The company develops gene therapies for rare genetic diseases using its proprietary Protein Splicing platform, a technology based on engineered split inteins originating from over 20 years of research at Princeton University's Muir Lab. SpliceBio's lead clinical program, SB-007, is a dual AAV gene therapy candidate in Phase 1/2 development (ASTRA study) for Stargardt disease, with the potential to treat all patients regardless of ABCA4 mutation type. The platform addresses a fundamental limitation in gene therapy: standard AAV vectors cannot package genes exceeding 4.7 kb, and SpliceBio's split intein technology reconstitutes full-length therapeutic proteins from dual AAV vectors in vivo.

SpliceBio's technology foundation combines engineered split inteins with additional proprietary elements enabling efficient delivery of large genes via dual AAV vectors, a platform that has been validated across multiple organs beyond the retina. The pipeline targets ophthalmology and neurology indications, and SB-007 has received FDA Orphan Drug Designation, FDA Fast Track Designation, European Commission Orphan Drug Designation, FDA IND clearance (the first-ever for a Protein Splicing gene therapy), and UK MHRA clearance. The company is supported by the POLARIS natural history study to streamline clinical trial enrollment.

SpliceBio is a privately held, pre-revenue biotech with no commercialized products. Its near-term revenue model is one-time licensing — exemplified by the October 2023 exclusive worldwide collaboration and licensing agreement with Spark Therapeutics for an undisclosed inherited retinal disease, eligible for up to $216 million in upfront, opt-in, and milestone payments plus royalties. Future revenue will derive from commercialization of SB-007 and pipeline gene therapy products, with pricing expected to be consistent with high-cost one-time gene therapies (industry reference points such as CSL's $3.5M hemophilia B therapy). The company pursues clinical trial site engagement, regulatory interactions, and biopharma partnerships, and is backed by over $200 million in total funding from top-tier investors including EQT Life Sciences, Sanofi Ventures, Roche Venture Fund, NEA, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.

Splice Bio firmographics

Firmographics
Name
Splice Bio
Legal name
SPLICEBIO, S.L.
Website
https://splice.bio
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
SpliceBio is a clinical-stage genetic medicines company developing gene therapies for rare genetic diseases using its proprietary Protein Splicing platform based on engineered split inteins from Princeton University. Its lead program, SB-007, is in Phase 1/2 trials for Stargardt disease.
Ownership category
akta.pro rank

Splice Bio industry classification

Industry
Product category
Genetic Medicines / Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy platform
  • Protein splicing technology
  • Dual AAV vectors
  • Ophthalmology therapeutics
  • Rare disease treatments

Where Splice Bio is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Splice Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Gene Therapy Development and Commercialization: Pre-revenue clinical-stage biotech company. Revenue will be generated through commercialization of gene therapy products, primarily SB-007 for Stargardt disease and future pipeline programs in ophthalmology, neurology, and other therapeutic areas. Additional potential revenue from licensing agreements and milestone payments from partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Splice Bio product offering

Product offering

Core offering

SpliceBio is a clinical-stage genetic medicines company developing gene therapies using its proprietary Protein Splicing platform based on engineered split inteins developed at Princeton University's Muir Lab. The platform enables delivery of large genes exceeding the 4.7 kb packaging capacity of standard AAV vectors by splitting genes across dual AAV vectors and reconstituting full-length therapeutic proteins in vivo via protein trans-splicing. The lead clinical candidate SB-007 is a dual AAV gene therapy for Stargardt disease currently in Phase 1/2 ASTRA clinical development.

Product overview

SpliceBio is a clinical-stage genetic medicines company offering a proprietary Protein Splicing platform technology and a pipeline of gene therapy programs. The core platform enables delivery of large genes using dual AAV vectors with engineered split inteins that reconstitute full-length therapeutic proteins in vivo. The lead product is SB-007, a dual AAV gene therapy for Stargardt disease currently in Phase 1/2 clinical development (ASTRA study), supported by the POLARIS natural history study. Additional pipeline programs span ophthalmology and neurology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • SB-007 Lead dual AAV gene therapy candidate for Stargardt disease that uses protein splicing technology to restore expression of full-length ABCA4 protein in retinal photoreceptor cells, with potential to treat all patients regardless of ABCA4 mutation type. Currently in Phase 1/2 ASTRA clinical trial; administered via subretinal injection.
  • Protein Splicing Platform Proprietary gene therapy technology platform based on engineered split inteins that enables delivery of large genes exceeding the 4.7 kb packaging capacity of standard AAV vectors. Splits large genes into multiple transgenes delivered via dual AAV vectors, which are reconstituted into full-length therapeutic proteins through protein trans-splicing in vivo. Licensed to biopharmaceutical partners for development of gene therapies in ophthalmology, neurology, and other therapeutic areas.

Quantifiable outcome

  • First patient dosed in Phase 1/2 ASTRA clinical trial in March 2025 - first dual AAV gene therapy for Stargardt disease to enter clinical development
  • +2 more outcomes

Companies that use Splice Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Splice Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Splice Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Spark TherapeuticscoreStrategic or Co-development Partner · 17 October 2023Exclusive collaboration and licensing agreement to utilize SpliceBio's Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Spark has exclusive worldwide rights to develop, manufacture, and commercialize. SpliceBio eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Splice Bio competitors and assessment

Company assessment

Direct peers

  • REGENXBIO: Clinical and commercial-stage AAV gene therapy company with a broad pipeline including ophthalmology assets (e.g., RGX-314 for wet AMD/DR). Direct platform peer in AAV-based gene therapy for rare diseases including inherited retinal conditions.
  • Adverum Biotechnologies: Clinical-stage AAV gene therapy company focused on ocular diseases (wet AMD, diabetic retinopathy). Directly comparable as an ophthalmology-focused AAV gene therapy peer at a similar clinical stage with intravitreal delivery approaches.
  • ProQR Therapeutics: Clinical-stage RNA therapeutics company developing ultevursen (formerly QR-421a) for Stargardt disease and other ophthalmology programs. Most direct competitor for SpliceBio's SB-007 lead indication, using antisense oligonucleotides rather than AAV gene therapy.
  • uniQure: Clinical and commercial-stage AAV gene therapy company (Hemgenix approved for hemophilia B). Comparable as a rare-disease AAV gene therapy platform with similar regulatory, manufacturing, and capital-intensity dynamics.
  • Voyager Therapeutics: Clinical-stage AAV gene therapy company focused on CNS and rare neurological diseases with proprietary capsid engineering. Similar stage and business model to SpliceBio, using engineered AAV vectors for hard-to-treat monogenic indications.
  • Passage Bio: Clinical-stage AAV gene therapy company developing treatments for rare CNS disorders, partnered with Penn's Gene Therapy Program. Comparable clinical-stage AAV peer in monogenic rare diseases.
  • Taysha Gene Therapies: Clinical-stage gene therapy company with a broad AAV-based pipeline across CNS and rare diseases. Comparable clinical-stage AAV gene therapy peer with similar platform strategy and indication breadth.

Emerging players

  • Nanoscope Therapeutics: Clinical-stage gene therapy company developing optogenetic therapies for retinal diseases including Stargardt disease (MCO-010). Directly competing in the same lead indication with an alternative gene-therapy-based mechanism.
  • Generation Bio: Clinical-stage non-viral gene therapy company using cell-targeted lipid nanoparticles (ctLNP) for large-gene delivery, including in ophthalmology and hemophilia. Emerging competitor pursuing the same large-gene delivery opportunity as SpliceBio but via a non-AAV modality.

Broad incumbents

  • BioMarin Pharmaceutical: Large rare-disease-focused biopharmaceutical company with a commercial gene therapy product (Roctavian for hemophilia A) and pipeline spanning ophthalmology, CNS, and metabolic rare diseases. A broader incumbent in the rare-disease gene therapy commercial landscape that SpliceBio's lead program could eventually compete in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

Splice Bio social profiles

Digital presence

Splice Bio compliance and trust

Trust signal

Compliance4 records

Splice Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Splice Bio leadership team

Management profile

Number of profiles

Profiles6 records

Splice Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Splice Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Splice Bio

What does Splice Bio do?

SpliceBio is a clinical-stage genetic medicines company developing gene therapies using its proprietary Protein Splicing platform based on engineered split inteins developed at Princeton University's Muir Lab. The platform enables delivery of large genes exceeding the 4.7 kb packaging capacity of standard AAV vectors by splitting genes across dual AAV vectors and reconstituting full-length therapeutic proteins in vivo via protein trans-splicing. The lead clinical candidate SB-007 is a dual AAV gene therapy for Stargardt disease currently in Phase 1/2 ASTRA clinical development.

Is Splice Bio a public or private company?

Splice Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Splice Bio founded?

Splice Bio was founded in 2014. It employs 51 to 100 people.

Where is Splice Bio based?

Splice Bio is headquartered in Barcelona, Spain, in the Europe region.

How does Splice Bio make money?

One revenue line is on record: gene Therapy Development and Commercialization.

Who are Splice Bio's main competitors?

Direct peers on record are REGENXBIO, Adverum Biotechnologies, ProQR Therapeutics, uniQure, Voyager Therapeutics, Passage Bio and Taysha Gene Therapies. Emerging players are Nanoscope Therapeutics and Generation Bio. BioMarin Pharmaceutical is listed as a broad incumbent.

Does Splice Bio have an API?

No public API is recorded for Splice Bio.

What industry is Splice Bio in?

Splice Bio's product category is Genetic Medicines / Gene Therapy. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAG, Ophthalmology Gene Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ophthalmology TimesFirst patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)SpliceBio dosed the first patient in its Phase 1/2 ASTRA study of SB-007, a dual AAV gene therapy for Stargardt disease. The therapy aims to restore full-length ABCA4 protein expression, and the company will share data at scientific conferences as the study progresses.Ophthalmology TimesFirst patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trialSpliceBio dosed the first patient in the dose-expansion portion of its phase 1/2 ASTRA trial for SB-007, a dual AAV gene therapy for Stargardt disease. The trial enrolls about 57 patients, with Part B randomized and controlled, and the FDA granted Fast Track designation. The company is also enrolling patients in its POLARIS natural history study.EIN PresswireGene Therapy Market to reach USD 41.63 Billion by 2035 at 19.04% CAGRThe global gene therapy market is projected to grow from USD 7.285 billion in 2025 to USD 41.63 billion by 2035, a CAGR of 19.04%. Growth is driven by rising genetic disorders, vector engineering, and regulatory streamlining, with North America leading at 45.75% of global revenue in 2024.EXPANSIONEl capital riesgo inyecta 150 millones de euros en empresas biomédicasVenture capital funds, business angels and startup incubators invested 172 million dollars (149 million euros) in Catalan life sciences companies in the first half of 2026, according to figures from consultancy JLL. This volume is 30% below the record 249 million dollars set in H1 2025, which was boosted by SpliceBio's 116-million-dollar mega-round — the largest in Spanish history — and excluding that operation, investment would have grown by 50% year-on-year. Notable 2026 rounds include Ona Therapeutics raising 74.2 million euros led by Columbus Venture and Mérieux Equity Partners, and Biorce capturing 53 million dollars for its AI-powered clinical trial platform.Empresas de Capital Riesgo en EspaStartup Investment in Spain Stabilizes at €3.1 Billion in 2025 with Record Activity LevelsSpanish startup investment reached €3.108 billion in 2025, a slight 3% decrease from €3.197 billion in 2024, despite an 11% increase in the number of operations to 376 rounds, according to the Startup Observatory annual report by the Bankinter Innovation Foundation. The market shifted toward smaller but more frequent deals, with mixed rounds co-invested by local and foreign investors surging 191% to €1.468 billion, while capital concentration in advanced phases raised concerns about early-stage funding. The largest capital raises were led by TravelPerk (€190M), Multiverse Computing (€189M), and Splice Bio (€118M).CrowdFund InsiderSpanish Investors Increasingly Backing Equity Deals Focused on AI and Climate Tech, Report RevealsAround 800 investors in Spain have backed equity deals this year, creating a more competitive environment where strategic positioning is considered crucial, according to CB Insights research. Kibo Ventures leads the ranking with 33 startup deals since 2023, with over one-fifth going to AI companies including Clarity AI and Theker. Ysios Capital Partners ranks highest in investment quality with an average Mosaic score of 715 out of 1,000, with top performers including Neurona Therapeutics and SpliceBio.Labiotech.euRaising money in uncertain times: how Splice Bio secured $135 million for its gene therapy playSplice Bio, a biotech company focused on gene therapy, closed a $135 million Series B fundraising round in 2025 despite challenging market conditions. Gerard Caelles, Chief Business Officer of Splice Bio, was interviewed on the Beyond Biotech podcast about the practical steps required to move from Series A to Series B, including building a fundraising team, engaging existing investors, and approaching new investors. The interview also covered fundraising challenges in 2025 and the company's next steps.Pulse 2.0SpliceBio: $135 Million Series B Raised For Expanding Pipeline Of Genetic MedicinesSpliceBio closed a $135 million Series B co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund and existing investors. The funds will advance clinical development of SB-007 for Stargardt disease and expand its AAV gene therapy pipeline. The company's Protein Splicing platform enables delivery of large genes beyond AAV packaging limits.TechStartupsTop 10 Startup and Tech Funding News – June 11, 2025Nine tech funding deals were reported on June 11, 2025, including Cyera's $540 million Series E and SpliceBio's $135 million Series B. Other rounds included Proxima Fusion's €130 million Series A and Wandercraft's $75 million Series D. Europe led with four of the nine raises.